Leadership update from VCHRI and M. H. Mohseni Institute of Urologic Sciences.
I am delighted to announce the appointment of Dr. Martin Gleave as the inaugural Chief Scientific Officer of the M. H. Mohseni Institute of Urologic Sciences, for a five-year term to December 5, 2029.
Dr. Gleave is a distinguished professor and chair of the Department of Urologic Sciences at the University of British Columbia (UBC) and a British Columbia Leadership Chair. A renowned surgeon-scientist, his groundbreaking research has focused on uncovering molecular mechanisms of treatment resistance in cancer and developing co-targeting strategies to enhance cancer control. Among Canada’s most cited and well-funded researchers, Dr. Gleave has authored over 650 publications, amassing more than 75,000 citations.
In recognition of his outstanding contributions, Dr. Gleave was appointed to the Order of Canada in 2017 for his pioneering work in prostate cancer treatment and his research on treatment resistance mechanisms. In 2020, he was inducted as a fellow of the National Academy of Inventors, underscoring his significant impact on cancer research and innovation. Dr. Gleave brings extensive leadership experience to this role, including serving as Director of the Vancouver Prostate Centre from 2006 to 2024. His vision and expertise position the Institute to achieve new levels of excellence in addressing unmet needs in urologic diseases.
As part of Vancouver Coastal Health Research Institute (VCHRI), the M. H. Mohseni Institute of Urologic Sciences is committed to translating scientific discoveries into clinical practice to improve the health and quality of life for British Columbians. Under Dr. Gleave’s leadership, the Institute will harness its integrated research cores to create a dynamic translational research environment for clinicians, surgeons and scientists. These efforts will drive advancements in diagnostics, prevention and therapeutic interventions across a wide spectrum of urologic conditions, including cancer, calculi, transplantation, reconstruction, neuro-urology, infertility, sexual health and pediatric transition care.
Please join me in congratulating Dr. Gleave on his appointment and extending our confidence in his leadership as he guides the M. H. Mohseni Institute of Urologic Sciences toward an exciting and impactful future.
Sincerely,
Teresa S.M. Tsang, MD, FRCPC, FACC, FASE
Executive Director, VCHRI
Associate Dean, Research, UBC Faculty of Medicine
